Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Brandon M. Huffman

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0768-3145; OpenAlex author ID A5041551628. Sources: ClinicalTrials.gov.

Their work

Papers
12
Trials
2 (principal investigator on 2)
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers, 1 trial · 2024: 2 papers · 2025: 1 paper · 2026: 4 papers · 2027: 1 trial

Papers 12

  1. Dendritic cell redundancy enables priming of anti-tumor CD4+ T cells in pancreatic cancer. Co-author DOI 10.1016/j.ccell.2026.04.005↗
  2. CD4 T cells convert transient responses to KRAS inhibition to durable remissions in pancreatic cancer. Co-author DOI 10.1016/j.cell.2026.08.045↗
  3. A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in ATM, BRCA1, BRCA2, PALB2, and CHEK2. Co-author DOI 10.1158/1078-0432.ccr-24-3766↗
  4. Cell-free chromatin epigenomic profiling enables non-invasive pancreatic cancer cell-state identification Co-author DOI 10.64898/2026.04.02.26349987↗
  5. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  6. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-24-1164↗
  7. Blockade of IL1β and PD1 with Combination Chemotherapy Reduces Systemic Myeloid Suppression in Metastatic Pancreatic Cancer with Heterogeneous Effects in the T… Co-author DOI 10.1158/2326-6066.cir-23-1073↗
  8. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal A… Co-author DOI 10.1001/jamanetworkopen.2022.49720↗
  9. A Phase I Expansion Cohort Study Evaluating the Safety and Efficacy of the CHK1 Inhibitor LY2880070 with Low-dose Gemcitabine in Patients with Metastatic Pancr… Co-author DOI 10.1158/1078-0432.ccr-23-2005↗
  10. Emerging Role of Targeted Therapy in Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.3390/cancers14246223↗
  11. Opportunities for Utilization of DNA Repair Inhibitors in Homologous Recombination Repair-Deficient and Proficient Pancreatic Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-21-1367↗
  12. Risk stratification using cytomorphologic features in endoscopic ultrasonographic-guided fine-needle aspiration diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/dc.23273↗

Trials 2

  1. Daraxonrasib in Resectable PDAC Principal investigator NCT07898813↗
  2. ZN-c3 + Gemcitabine in Pancreatic Cancer Principal investigator NCT06015659↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Brian Matthew Wolpin · 11 shared papers, 2021–2026 · strength 1.73
  2. James M. Cleary · 11 shared papers, 2021–2026 · strength 1.73
  3. Harshabad Singh · 10 shared papers, 2021–2026 · strength 1.58
  4. Kimberly J. Perez · 9 shared papers, 2022–2026 · strength 1.46
  5. Jonathan Andrew Nowak · 8 shared papers, 2021–2026 · strength 1.32
  6. Andrew J. Aguirre · 8 shared papers, 2021–2026 · strength 1.26
  7. Douglas Adam Rubinson · 7 shared papers, 2022–2026 · strength 1.12
  8. Stephanie K. Dougan · 5 shared papers, 2021–2026 · strength 0.79
  9. Srivatsan Raghavan · 5 shared papers, 2021–2026 · strength 0.75
  10. Leah H. Biller · 4 shared papers, 2023–2026 · strength 0.60
  11. Rishi Surana · 4 shared papers, 2022–2025 · strength 0.58
  12. Joseph Douglas Mancias · 3 shared papers, 2025–2026 · strength 0.53
  13. Michael Lawrence Dougan · 3 shared papers, 2024–2026 · strength 0.51
  14. Matthew B.B. Yurgelun · 3 shared papers, 2024–2026 · strength 0.48
  15. Andressa Dias Costa · 3 shared papers, 2024–2026 · strength 0.47
  16. Kimmie Ng · 3 shared papers, 2023–2026 · strength 0.47
  17. Alan D. D’Andrea · 3 shared papers, 2021–2026 · strength 0.44
  18. Geoffrey Ira Shapiro · 3 shared papers, 2021–2026 · strength 0.44
  19. Thomas Adam Abrams · 3 shared papers, 2023–2025 · strength 0.42
  20. Courtney T.S. Kureshi · 2 shared papers, 2026 · strength 0.38
  21. Chong Zuo · 2 shared papers, 2026 · strength 0.38
  22. George Molina · 2 shared papers, 2026 · strength 0.38
  23. Thomas E. Clancy · 2 shared papers, 2026 · strength 0.38
  24. Mary Linton B. Peters · 2 shared papers, 2025–2026 · strength 0.34
  25. Andrea J. Bullock · 2 shared papers, 2025–2026 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.